Press Releases Year None20202019201820172015 October 19, 2020 ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program October 9, 2020 ORIC Pharmaceuticals Announces Presentation of Preclinical Data on Glucocorticoid Receptor Antagonist Overcoming Resistance to an Androgen Receptor Degrader at the 32nd EORTC-NCI-AACR Symposium 2020 September 2, 2020 ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences August 5, 2020 ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update August 5, 2020 ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics August 3, 2020 ORIC Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call June 22, 2020 ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting II June 9, 2020 ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors May 27, 2020 ORIC Pharmaceuticals Announces Five Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II May 26, 2020 ORIC Pharmaceuticals to Present at the Jefferies 2020 Global Healthcare Conference Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 18
